Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Public ClinicalTrials.gov record NCT01068782. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Non-Comparative Randomized Open-Label Study of Multiple Regimens of Single-Agent XL184 in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Study identification
- NCT ID
- NCT01068782
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Exelixis
- Industry
- Enrollment
- 19 participants
Conditions and interventions
Conditions
Interventions
- Cabozantinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2010
- Primary completion
- Apr 30, 2011
- Completion
- Sep 30, 2013
- Last update posted
- Feb 24, 2026
2010 – 2013
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35294 | — |
| Not listed | Encinitas | California | 92024 | — |
| Not listed | Pleasant Hill | California | 94523 | — |
| Not listed | Chicago | Illinois | 60611 | — |
| Not listed | Chicago | Illinois | 60637 | — |
| Not listed | Boston | Massachusetts | 02115 | — |
| Not listed | Detroit | Michigan | 48202 | — |
| Not listed | Minneapolis | Minnesota | 55407 | — |
| Not listed | Amherst | New York | 14226 | — |
| Not listed | Rochester | New York | 14642 | — |
| Not listed | Cleveland | Ohio | 44195 | — |
| Not listed | Hershey | Pennsylvania | 17033 | — |
| Not listed | Dallas | Texas | 75246 | — |
| Not listed | Dallas | Texas | 75426 | — |
| Not listed | San Antonio | Texas | 78229 | — |
| Not listed | Charlottesville | Virginia | 22908 | — |
| Not listed | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01068782, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 24, 2026 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01068782 live on ClinicalTrials.gov.